In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol Revs Its R&D Engine: An Interview with Elliott Sigal and Francis Cuss

Executive Summary

Just one year ago, Bristol-Myers Squibb's days as an independent entity seemed numbered. But thanks to the resolution of the Plavix crisis, innovative deal-making, and an R&D pipeline surging with specialty-focused products, the company is now thriving. In a free-wheeling Q&A, Bristol's R&D gurus, Francis Cuss and Elliott Sigal, discuss the need for a new kind of biopharma that is specialty-focused and technology agnostic.

Related Content

With The Launch Of Yervoy, Early Signs Of R&D Success For Bristol
Can BMS Deliver on Innovation?
Pharma's New Follow-On Strategy
Biopharma: Reviewing 2007 to Forecast 2008
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2007
Pfizer Deal Highlights Bristol's Biotech Swagger
Overheard at JP Morgan's 25th Health Care Conference: Making Up for Lost Drugs: Pharma Attempts to Appease Investors
BMS Deals Diabetes Drugs, Solidifies Specialist Stance
Generic Plavix: As Bristol Swoons, Broad Implications
Generic Plavix: As Bristol Swoons, Broad Implications


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts